Sell4

Veradermics, Inc

MANE

Total Value

$80.4M

Net $80.4M sold

Filing Date

Aug 21, 2026

2 transactions

Sales

$80.4M

2 transactions

Trade Summary

On Aug 19, 2026 through Aug 20, 2026, MONTANOVA CAPITAL, LLC, Insider, sold $80.4M of Veradermics, Inc (MANE) across 2 transactions. The filing covers Common stock, par value $0.00001 per share and reflects net selling of $80.4M. Reported prices ranged from $107.25. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

MANE daily price with the insider's sale marked at $107.25.

Sold in the upper half of the 6-month range · the stock trades 4% lower today.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: MONTANOVA CAPITAL, LLC
Role: Insider
Location: NEW YORK, NY

Filing Details

Filing Date: Aug 21, 2026
Transaction Date: Aug 19, 2026
Accession Number: 0000899140-26-000947
Form Type: 4
Net Trading Amount: -$80.4M

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Aug 19, 2026	Common stock, par value $0.00001 per share	690,601	$107.25	Sale	$74.1M
Aug 19, 2026	Common stock, par value $0.00001 per share	59,399	$107.25	Sale	$6.4M
Aug 20, 2026	Common stock, par value $0.00001 per share	149,000	—	Exercise	—
Aug 20, 2026	Common stock, par value $0.00001 per share	151,000	—	Exercise	—

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Aug 20, 2026	MANE derivative	149,000	—	Exercise	—
Aug 20, 2026	MANE derivative	151,000	—	Exercise	—

Want live alerts when MONTANOVA CAPITAL, LLC trades again?

Download Insider Trades to track MANE, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Notes are included on Exhibit 99.1.
(F2)Notes are included on Exhibit 99.1.
(F3)Notes are included on Exhibit 99.1.
(F4)Notes are included on Exhibit 99.1.
(F5)Notes are included on Exhibit 99.1.
(F6)Notes are included on Exhibit 99.1.
(F7)Notes are included on Exhibit 99.1.
(F8)Notes are included on Exhibit 99.1.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MONTANOVA CAPITAL, LLC

(Last)

(First)

(Middle)

11 E 26TH STREET

16TH FLOOR

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock, par value $0.00001 per share	08/19/2026		S		690,601⁽²⁾	D	$107.25	2,957,937	I⁽¹⁾	See footnotes⁽¹⁾⁽²⁾
Common stock, par value $0.00001 per share	08/19/2026		S		59,399⁽³⁾	D	$107.25	461,033	I⁽¹⁾	See footnotes⁽¹⁾⁽³⁾
Common stock, par value $0.00001 per share	08/20/2026		X		149,000⁽⁴⁾	A	⁽⁶⁾	3,106,937	I⁽¹⁾	See footnotes⁽¹⁾⁽⁴⁾
Common stock, par value $0.00001 per share	08/20/2026		X		151,000⁽⁵⁾	A	⁽⁶⁾	612,033	I⁽¹⁾	See footnotes⁽¹⁾⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Pre-Funded Warrants	⁽⁶⁾	08/20/2026		X			149,000⁽⁴⁾	⁽⁷⁾⁽⁸⁾	⁽⁷⁾	Common Stock	149,000⁽⁷⁾	$0	0	I⁽¹⁾	See footnotes⁽¹⁾⁽⁴⁾
Pre-Funded Warrants	⁽⁶⁾	08/20/2026		X			151,000⁽⁵⁾	⁽⁷⁾⁽⁸⁾	⁽⁷⁾	Common Stock	151,000⁽⁷⁾	$0	0	I⁽¹⁾	See footnotes⁽¹⁾⁽⁵⁾

1. Name and Address of Reporting Person^*

MONTANOVA CAPITAL, LLC

(Last)

(First)

(Middle)

11 E 26TH STREET

16TH FLOOR

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

1. Name and Address of Reporting Person^*

Cowen Aaron

(Last)

(First)

(Middle)

C/O MONTANOVA CAPITAL, LLC

11 E 26TH, 16TH FLOOR

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See footnotes

1. Name and Address of Reporting Person^*

Averill Master Fund, Ltd.

(Last)

(First)

(Middle)

C/O MONTANOVA CAPITAL, LLC

11 E 26TH, 16TH FLOOR

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

1. Name and Address of Reporting Person^*

Averill Madison Master Fund, Ltd.

(Last)

(First)

(Middle)

C/O MONTANOVA CAPITAL, LLC

11 E 26TH, 16TH FLOOR

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

Explanation of Responses:

1. Notes are included on Exhibit 99.1.

2. Notes are included on Exhibit 99.1.

3. Notes are included on Exhibit 99.1.

4. Notes are included on Exhibit 99.1.

5. Notes are included on Exhibit 99.1.

6. Notes are included on Exhibit 99.1.

7. Notes are included on Exhibit 99.1.

8. Notes are included on Exhibit 99.1.

Remarks:

Exhibit List: Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filer Information Exhibit 99.3 - Joint Filers' Signature

	Montanova Capital, LLC; By: /s/ Andrew Nathanson, General Counsel & Chief Compliance Officer	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0000899140-26-000947.

Veradermics, Inc

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when MONTANOVA CAPITAL, LLC trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4

Price at the Time of the Trade